Atezolizumab plus Bevacizumab versus Sorafenib for Unresectable Hepatocellular Carcinoma: Results from Older Adults Enrolled in the IMbrave150 Randomized Clinical Trial — Daneng Li (2022) | RDL Network
Atezolizumab plus Bevacizumab versus Sorafenib for Unresectable Hepatocellular Carcinoma: Results from Older Adults Enrolled in the IMbrave150 Randomized Clinical Trial
Article 2022 en
Authors
DL
Daneng Li
HT
Han Chong Toh
PM
Philippe Merle
Abstract
1 min read
Atezolizumab plus bevacizumab is safe and effective in adults <65, ≥65 to <75, and ≥75. Treatment was well-tolerated even in elderly patients.
Margherita Rimini, Lorenza Rimassa, Kazuomi Ueshima, Valentina Burgio, S. Shigeo, Toshifumi Tada, Goki Suda, Chi‐Hyeon Yoo, Jaekyung Cheon, David J. Pinato, Sara Lonardi, Mario Scartozzi, Massimo Iavarone, G.G. Di Costanzo, Fabio Marra, Caterina Soldà, Emiliano Tamburini, Fabio Piscaglia, Gianluca Masi, Giuseppe Cabibbo, Francesco Giuseppe Foschi, Marianna Silletta,
Discussion(0)
No comments yet. Be the first to comment.